Sign in
CompletedNo phase

Analyzing Preoperative Stereotactic Radiosurgery With Gamma Knife Icon for Brain Metastases

Key facts

Who runs it
Medical College of Wisconsin
Where
Milwaukee, United StatesSee the site
Trial code
Status
Completed
People taking part
11 people enrolled
Started
15 Jan 2021
Ended
22 Aug 2024
Type of study
Interventional
Treatments tested
  • Stereotactic Radiosurgery
  • Surgical Resection
  • Magnetic Resonance Imaging
Record updated
24 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (24)Hide the full registry criteria

Who can take part

  • Voluntary written consent must be given before performance of any study related procedure that's is not part of standard medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
  • Female or Male subject's ≥ 18 years old at the time of informed consent
  • Radiographically confirmed solid tumor brain metastases
  • Criteria for surgical resection of at least one metastasis per neurosurgeon discretion
  • Stereotactic radiosurgery candidate per radiation oncologist discretion
  • A diagnostic MRI Brain or CT Head demonstrating the presence of 1-4 solid tumor brain metastases and lesion to be resected no more than 5 cm in any direction, performed within 30 days prior to stereotactic radiosurgery
  • For known and unknown primary, diagnosis-specific graded prognostic assessment (ds-GPA) estimated median survival no less than 6 months
  • Surgical resection able to be performed within 1-10 days after radiosurgery
  • Patients currently on cytotoxic chemotherapy or immunotherapy are eligible, not including anti-vascular endothelial growth factor (anti-VEGF) therapy
  • Female subjects who:; Are postmenopausal for at least 1 year before the screening visit, OR; Are surgically sterile, OR; Agree to practice 1 highly effective method and 1 additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through 4 months after the last study Intervention (female and male condoms should not be used together), OR ii. Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception.)
  • Male subjects, even if surgically sterilized (ie, status post-vasectomy), who:; Agree to practice effective barrier contraception during the entire study treatment period from the time of signing the informed consent through and through 4 months after the last study Intervention (female and male condoms should not be used together), OR; Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods for the female partner] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception.)

Who cannot take part

  • Patients who received anti-VEGF therapy within 6 weeks prior to enrollment, as there is increased risk of fatal brain hemorrhage with surgical resection
  • Previous whole brain radiation therapy
  • Previous radiation therapy to the lesion to be resected
  • Planned adjuvant focal therapy including additional radiation therapy to the brain
  • Not a surgical candidate per neurosurgeon discretion
  • Not a stereotactic radiosurgery candidate per radiation oncologist discretion
  • Surgery unable to be performed between 1 - 10 days after radiosurgery
  • Major medical illnesses or psychiatric impairments, which in the investigator's opinion will prevent administration or completion of the protocol therapy and/or interfere with surveillance
  • Patients with more than 4 brain metastases on MRI Brain
  • Lesion to be resected is more than 5 cm in any dimension
  • Patients with leptomeningeal metastases documented by MRI or cerebrospinal fluid (CSF) evaluation
  • Women who are pregnant or nursing as treatment involves unforeseeable risks to the fetus or child
  • Patients who have a known or unknown primary and have an estimated median survival of less than 6 months per ds-GPA

Where in United States

  • Froedtert Hospital/Medical College of WisconsinMilwaukee, United States

About the trial

What the trial wants to find out

This is a single-arm, single-center pilot study in which 10 patients with one to four brain metastases diagnosed on brain magnetic resonance imaging (MRI) within the past 30 days will be evaluated for study eligibility and enrolled as appropriate.

The group in the trial

  • Stereotactic RadiosurgeryTreatment being tested

    SRS will be delivered utilizing gamma knife or linear accelerator-based techniques.

    Treatment: Stereotactic Radiosurgery, Surgical Resection, and Magnetic Resonance Imaging

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Pilot Study Analyzing Preoperative Stereotactic Radiosurgery (SRS) With Gamma Knife (GK) for Brain Metastases
Record updated
24 March 2026